EBOS GROUP LIMITED (EBO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EBO

EBO - EBOS GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 2.84
Index: ASX300 | ALL-ORDS

EBOS Group distributes healthcare, pharmaceutical and animal-care products and provides related services across Australasia.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$18.62

13 Jul
2026

0.640

OPEN

$17.91

3.56%

HIGH

$18.79

161,309

LOW

$17.91

TARGET
$25.64 37.7% upside
Franking for last dividend paid out: 95%
OTHER COMPANIES IN THE SAME SECTOR
ACL . ALC . BMT . DOC . HLS . IDX . M7T . MPL . MVF . NHF . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
EBO: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 109.7 123.1 xxx
DPS (cps) xxx 112.9 102.9 xxx
EPS Growth xxx - 22.4% 12.2% xxx
DPS Growth xxx N/A - 8.8% xxx
PE Ratio xxx N/A 15.3 xxx
Dividend Yield xxx N/A 5.5% xxx
Div Pay Ratio(%) xxx 102.9% 83.6% xxx

Dividend yield today if purchased 3 years ago: 3.24%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 6.01

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/09 - ex-div 49.19c (franking 95%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic 100.6113.2114.5132.9141.3109.7
DPS All 76.886.094.0107.9114.5112.9
Sales/Revenue 8,765.5 M9,202.9 M10,734.1 M12,237.4 M13,189.1 M12,266.9 M
Book Value Per Share 807.4859.51,195.91,270.51,268.41,348.0
Net Operating Cash Flow 229.2 M298.3 M248.7 M391.4 M348.2 M418.5 M
Net Profit Margin 1.85 %2.01 %1.89 %2.07 %2.06 %1.75 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed 12.71 %13.59 %11.02 %10.78 %11.12 %8.29 %
Return on Invested Capital 9.42 %9.80 %7.40 %7.07 %7.88 %5.70 %
Return on Assets 4.68 %4.82 %3.97 %3.99 %4.12 %3.07 %
Return on Equity 12.71 %13.59 %11.02 %10.78 %11.12 %8.29 %
Return on Total Capital 13.37 %13.68 %11.75 %12.06 %12.64 %10.08 %
Free Cash Flow ex dividends 93.1 M96.2 M12.9 M121.6 M96.2 M156.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt 281 M153 M374 M92 M823 M82 M
Long Term Debt 528 M527 M1,273 M1,191 M820 M1,540 M
Total Debt 809 M680 M1,648 M1,283 M1,643 M1,622 M
Goodwill - Gross 970 M999 M2,140 M1,976 M2,068 M2,245 M
Cash & Equivalents - Generic 245 M169 M517 M212 M217 M184 M
Price To Book Value 2.503.502.952.662.322.64

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex 29.3 M82.3 M89.6 M98.4 M118.8 M146.0 M
Capex % of Sales 0.33 %0.89 %0.84 %0.80 %0.90 %1.19 %
Cost of Goods Sold 8,236 M8,634 M9,985 M11,322 M12,232 M11,346 M
Selling, General & Admin. Exp & Other 269 M281 M404 M470 M474 M497 M
Research & Development ------
Investments - Total 57 M57 M59 M69 M89 M95 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

23/04/2026

1

Buy

$22.92

23.09%

EBOS Group has downgraded FY26 earnings (EBITDA) guidance by around -2% at the midpoint, citing elevated fuel and energy costs.

Higher input costs, particularly across distribution operations, are being largely absorbed, with limited ability to pass through pricing due to the essential nature of its services, the analysts explain.

EPS forecasts are downgraded across FY26-FY28. Near-term growth is expected to remain subdued following a period of heavy investment.

Morgans lowers its target to $22.92 from $28.07 but retains a Buy rating, highlighting attractive yield and an expected growth recovery from FY28.

FORECAST
Morgans forecasts a full year FY26 dividend of 107.00 cents and EPS of 120.60 cents.
Morgans forecasts a full year FY27 dividend of 106.00 cents and EPS of 120.70 cents.

Citi

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

05/06/2026

2

Overweight

-

-

Jarden maintains an Overweight rating for Ebos Group with its target price reduced to NZ$30.50 from NZ$33.80 following an intermediate reset of earnings growth trajectories under new group leadership.

As the report explains, core community pharmacy segments experience distinct margin decompression from near-term supply chain fuel hikes and structural volume reallocations following the loss of the Chemist Warehouse Australia contract.

Jarden states step acquisition triggers under financial reporting frameworks alter the consolidation profile of Origin Biologics, moving the entity from an equity-accounted associate to a fully controlled subsidiary.

Operational revenues for FY26 are projected to climb to $13,657.7m, supported by resilient growth across residual medical technology lines and regional bolt-on acquisitions.

Normalised earnings per share estimates contract -8.2% in FY26 to 120.6c, capturing a deeper reset duration before core group baseline expansion is expected to resume in FY28.

FORECAST
Jarden forecasts a full year FY26 dividend of 100.00 cents and EPS of 120.60 cents.
Jarden forecasts a full year FY27 dividend of 96.00 cents and EPS of 117.00 cents.
Access Extra Coverage Research History >

EBO STOCK CHART

FNArena News on EBO

1
Australian Broker Call *Extra* Edition – Jun 05, 2026

Jun 05 2026 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – May 04, 2026

May 04 2026 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Mar 23, 2026

Mar 23 2026 - Daily Market Reports
4
Next Week At A Glance – 23-27 Mar 2026

Mar 20 2026 - Weekly Reports
5
Australian Broker Call *Extra* Edition – Mar 05, 2026

Mar 05 2026 - Daily Market Reports

Latest Healthcare services News

1
Major UK Win Highlights Alcidion’s Potential

May 27 2026 - Small Caps
2
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
3
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
4
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
5
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
6
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
7
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
8
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
9
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
10
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia